Microarray data and pathway analyses for primary human activated hepatic stellate cells compared to HepG2 human hepatoma cells

Alexandra M Hetherington; Cynthia G Sawyez; Nica M Borradaile

doi:10.1016/j.dib.2016.12.011

Microarray data and pathway analyses for primary human activated hepatic stellate cells compared to HepG2 human hepatoma cells

Data Brief. 2016 Dec 13:10:385-389. doi: 10.1016/j.dib.2016.12.011. eCollection 2017 Feb.

Authors

Alexandra M Hetherington¹, Cynthia G Sawyez¹, Nica M Borradaile¹

Affiliation

¹ Department of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.

Abstract

As nonalcoholic fatty liver disease progresses to end-stage diseases, including fibrosis, cirrhosis and hepatocellular carcinoma, fibrotic activated hepatic stellate cells and cancerous epithelial cells can become abundant, changing the cellular composition of this organ. Despite potentially residing within the same diseased tissue, direct comparisons of global gene expression between activated hepatic stellate cells and hepatocellular carcinoma cells are lacking. Here we provide data collected using Affymetrix GeneChip microarrays to identify differential gene expression in cultured primary human activated hepatic stellate cells compared to HepG2 human hepatoma cells. The dataset includes many genes involved in intermediary metabolism which were investigated in greater depth in our associated article (A.M. Hetherington, C.G. Sawyez, E. Zilberman, A.M. Stoianov, D.L. Robson, J.M. Hughes-Large, et al., 2016) [1]. Pathway analyses of known protein coding genes down-regulated or up-regulated by greater than 2.0-fold are also provided.

Keywords: Hepatocyte; Liver; NAFLD; Stellate cell.